EPISODE · May 4, 2026 · 1 MIN
AbbVie's Stock Surge: Skyrizi & Rinvoq Power Growth
from The Daily News Now! Business
AbbVies stock surged after their first-quarter update, with revenue hitting $15 billion, a 12.4% increase from last year. The companys immunology segment, led by Skyrizi and Rinvoq, is driving growth, with sales guidance raised multiple times. Label expansions and strong patents are also boosting investor confidence. Despite a recent dip, AbbVies robust pipeline and Dividend King status make it a solid hold. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7ddc2db27d56aee7
NOW PLAYING
AbbVie's Stock Surge: Skyrizi & Rinvoq Power Growth
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m